Biophytis S.A. (PA:ALBPS) — Market Cap & Net Worth
Market Cap & Net Worth: Biophytis S.A. (ALBPS)
Biophytis S.A. (PA:ALBPS) has a market capitalization of $314.94K (€269.39K) as of August 1, 2026. Listed on the PA stock exchange, this France-based company holds position #31069 globally and #587 in its home market, demonstrating a -58.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biophytis S.A.'s stock price €0.01 by its total outstanding shares 42091628 (42.09 Million). See ALBPS capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Biophytis S.A. Market Cap History: 2015 to 2026
Biophytis S.A.'s market capitalization history from 2015 to 2026. Data shows change from $225.97 Billion to $314.94K (-71.47% CAGR).
Biophytis S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biophytis S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALBPS by Market Capitalization
Companies near Biophytis S.A. in the global market cap rankings as of August 1, 2026.
Key companies related to Biophytis S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Biophytis S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Biophytis S.A.'s market cap moved from $225.97 Billion to $ 314.94K, with a yearly change of -71.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €314.94K | -90.32% |
| 2025 | €3.25 Million | -82.60% |
| 2024 | €18.69 Million | -81.38% |
| 2023 | €100.39 Million | -88.91% |
| 2022 | €905.46 Million | -90.71% |
| 2021 | €9.74 Billion | -46.26% |
| 2020 | €18.13 Billion | +362.81% |
| 2019 | €3.92 Billion | -88.29% |
| 2018 | €33.46 Billion | -63.75% |
| 2017 | €92.32 Billion | +21.50% |
| 2016 | €75.98 Billion | -66.38% |
| 2015 | €225.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Biophytis S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $314.94K USD |
| MoneyControl | $314.94K USD |
| MarketWatch | $314.94K USD |
| marketcap.company | $314.94K USD |
| Reuters | $314.94K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more